The in vitro activity of sparfloxacin (AT-4140; RP 64206), a new fluoroquinolone, was compared with those of 10 other agents against 1,222 clinical isolates. Sparfloxacin and ciprofloxacin were the most active quinolones against members of the family Enterobacteriaceae and nonfermenting gram-negative bacilli; sparfloxacin had superior activity against gram-positive cocci in comparison with the activities of ciprofloxacin and the other quinolones tested (norfloxacin, lomefloxacin, and pefloxacin Briefly, the standardized inoculum was prepared by inoculating the strains into a tube containing Iso-Sensitest broth (Oxoid, Basingstoke, United Kingdom). The bacterial suspension was incubated at 35°C until it was visibly turbid. For some species (streptococci, Listeria monocytogenes, Yersinia enterocolitica, Neisseria spp., Branhamella catarrhalis, Legionella pneumophila, Campylobacterjejuni, and Helicobacter pylori), inocula with the proper densities were prepared with bacteria from colonies on an overnight agar plate (direct method). The bacterial suspension was adjusted to 108 CFU/ml and diluted 1:10 to obtain the desired inoculum concentration of 107 CFU/ml. With a multipoint inoculating device (Denley-Tech, Billingshurst, United Kingdom), 1 ,ul of the adjusted bacterial suspension was applied to the freshly prepared antibiotic-containing agar plates, for an inoculum of 104 CFU per spot. Iso-Sensitest agar (Oxoid) was used for the agar dilution procedure. Sheep erythrocytes (5%) were added to the medium when streptococci, Branhamella catarrhalis, Yersinia enterocolitica, Campylobacter jejuni, and Helicobacter pylori were tested. For Neisseria gonorrhoeae, GC agar with 1% defined supplement (Difco, Detroit, Mich.) was used. For Legionella pneumophila, buffered charcoal-yeast extract medium supplemented with a-ketoglutarate without charcoal was used. The agar was supplemented with p-nitrophenyl glycerol (50 ,ug/ml; Sigma, St. Louis, Mo.) when Proteus spp. were tested, to prevent swarming. The antimicrobial activity against Haemophilus influenzae was determined in Haemophilus test medium by a broth microdilution assay with a final inoculum of 5 x 105 CFU/ml. For anaerobic bacteria, the agar dilution method described by Sutter (9) was used on Wilkins-Chalgren agar with 5 ,ug of hemin per ml and 0.5 ,ug of vitamin K1 (Difco) per ml. The MIC was defined as the lowest concentration at which no visible growth was observed. One colony 858 on November 6, 2017 by guest http://aac.asm.org/ Downloaded from
The fluorinated quinolones are a rapidly expanding group of antimicrobial agents. These new agents have excellent activity against many gram-negative bacteria, including members of the family Enterobacteriaceae, nonfermenting bacilli, Neisseria spp., and Haemophilus spp. (10) . However, most quinolones have less activity against such gram-positive pathogens as Streptococcus pneumoniae, Staphylococcus aureus, and beta-hemolytic streptococci. Sparfloxacin (AT-4140; RP 64206) was selected as an agent with a broader spectrum, with improved activity against gram-positive bacteria, Mycobacterium spp., Chlamydia spp., and Mycoplasma spp. (4, 6) . In animal and human studies, sparfloxacin has shown interesting pharmacokinetic properties (5) and good tissue penetration (3) . The purpose of the present study was to investigate the in vitro activity of sparfloxacin and to compare its activity with those of other quinolones and other antimicrobial agents against a wide range of clinical isolates.
MATERIALS AND METHODS
Antimicrobial agents. The following antimicrobial agents were provided by the indicated manufacturers: sparfloxacin (lot T 89006), pefloxacin, and metronidazole, Rhone-Poulenc, Antony, France; ciprofloxacin, Bayer, Mijdrecht, The Netherlands; norfloxacin and imipenem, Merck Sharp & Dohme, Haarlem, The Netherlands; lomefloxacin, Searle, Maarssen, The Netherlands; ceftazidime, Glaxo BV, Nieuwegein, The Netherlands; gentamicin, Bufachemie, Castricum, The Netherlands; amikacin, Bristol-Myers, Woerden, The Netherlands; piperacillin, Lederle, Etten-Leur, The Netherlands; and amoxicillin and clavulanic acid, Beecham Research Laboratories, Rijswijk, The Netherlands. Amoxicillin was combined with clavulanic acid in a final ratio of 2:1. Antimicrobial agents were stored, dissolved, and diluted by the recommendations of the manufacturer or those of the National Committee for Clinical Laboratory Standards (7) . Fresh dilutions of all compounds were made daily.
Organisms tested. The microorganisms used in this study * Corresponding author.
were routine clinical isolates collected between 1983 and 1989; the strains were identified by standard methods. Each strain was stored at -70°C in skim milk until use. Antimicrobial susceptibility testing. Antimicrobial activities against all strains except Haemophilus influenzae (see below) were measured by a routine agar dilution method. Briefly, the standardized inoculum was prepared by inoculating the strains into a tube containing Iso-Sensitest broth (Oxoid, Basingstoke, United Kingdom). The bacterial suspension was incubated at 35°C until it was visibly turbid. For some species (streptococci, Listeria monocytogenes, Yersinia enterocolitica, Neisseria spp., Branhamella catarrhalis, Legionella pneumophila, Campylobacterjejuni, and Helicobacter pylori), inocula with the proper densities were prepared with bacteria from colonies on an overnight agar plate (direct method). The bacterial suspension was adjusted to 108 CFU/ml and diluted 1:10 to obtain the desired inoculum concentration of 107 CFU/ml. With a multipoint inoculating device (Denley-Tech, Billingshurst, United Kingdom), 1 ,ul of the adjusted bacterial suspension was applied to the freshly prepared antibiotic-containing agar plates, for an inoculum of 104 CFU per spot. Iso-Sensitest agar (Oxoid) was used for the agar dilution procedure. Sheep erythrocytes (5%) were added to the medium when streptococci, Branhamella catarrhalis, Yersinia enterocolitica, Campylobacter jejuni, and Helicobacter pylori were tested. For Neisseria gonorrhoeae, GC agar with 1% defined supplement (Difco, Detroit, Mich.) was used. For Legionella pneumophila, buffered charcoal-yeast extract medium supplemented with a-ketoglutarate without charcoal was used. The agar was supplemented with p-nitrophenyl glycerol (50 ,ug/ml; Sigma, St. Louis, Mo.) when Proteus spp. were tested, to prevent swarming. The antimicrobial activity against Haemophilus influenzae was determined in Haemophilus test medium by a broth microdilution assay with a final inoculum of 5 x 105 CFU/ml. For anaerobic bacteria, the agar dilution method described by Sutter (9) was used on Wilkins-Chalgren agar with 5 ,ug of hemin per ml and 0.5 ,ug of vitamin K1 (Difco) per ml. The MIC was defined as the lowest concentration at which no visible growth was observed. One colony were inoculated daily along with the studied strains onto each agar plate. When anaerobic bacteria were tested, Bacteroides fragilis ATCC 25285 was used as a control strain; when amoxicillin-clavulanic acid was tested, Escherichia coli ATCC 35218 was used as a control strain. When Haemophilus influenzae and Neisseria gonorrhoeae were tested, Haemophilus influenzae ATCC 49247 and Neisseria gonorrhoeae ATCC 49226 were included in the controls, respectively. The MICs of ciprofloxacin, norfloxacin, amoxicillin-clavulanic acid, piperacillin, imipenem, gentamicin, amikacin, and metronidazole for these American Type Culture Collection (ATCC) strains were within the published acceptable quality control range (7) . For sparfloxacin, the MIC in the present study for Escherichia coli ATCC 25922 was .0.06 to 0.12 [Lg/ml (median, .0.06 p.g/ml; n = 79); the median sparfloxacin MIC for Pseudomonas aeruginosa ATCC 27853 was 2 ,ug/ml (range, 1 to 8 ,ug/ml; n = 76); for Bacteroides fragilis ATCC 25285, the sparfloxacin MIC was always 1 ,ug/ml (n = 4) when tested in an anaerobic environment. For both Haemophilus influenzae ATCC 49247 and Neisseria gonorrhoeae ATCC 49226, the sparfloxacin MICs were <0.06 pLg/ml. MICs in the broth dilution assay were the same or within 1 to 2 dilution steps of those determined by the agar dilution method with a similar medium and pH.
RESULTS
Susceptibilities of clinical isolates. Results of the susceptibility studies are shown in Tables 1 and 2 . Overall, the sparfloxacin MIC for 50% (MlC50) of members of the family of Enterobacteriaceae was .0.06 VLg/ml, while the MIC for 90% (MIC90) of members of the family Enterobacteriaceae was 0.5 p.g/ml. For the different species of the Enterobacteriaceae separately, the concentration of sparfloxacin which inhibited 90% of strains was always <1 jxg/ml; those for Citrobacterfreundii (MIC90, 2 p.g/ml) and Serratia marcescens (MIC90, 8 pg/ml) were not, however. Included among the Enterobacteriaceae were strains that were resistant to amoxicillin-clavulanic acid, piperacillin, ceftazidime, and the aminoglycosides. The concentration of sparfloxacin that inhibited 90% of Pseudomonas aeruginosa strains was 4 jig/ml; the MIC90s for Xanthomonas maltophilia and Acinetobacter calcoaceticus were 1 ,ug/ml. Sparfloxacin inhibited Haemophilus influenzae, Branhamella catarrhalis, Neisseria spp., and Legionella pneumophila at concentrations of <0.12 jg/ml; among the inhibited microorganisms were many P-lactamase-producing strains. Sparfloxacin had good activity against several enteropathogens (Campylobacter jejuni, Helicobacter pylori, Aeromonas hydrophila, Salmonella spp., and Shigella spp.) and against the anaerobic pathogens Bacteroides fragilis group and Clostridium perfringens (MIC90, 2 ,ug/ml).
Against the gram-positive cocci ( tion of infection with gram-negative bacteria (8) . Sparfloxacin has been reported to yield a mean level of The high activity of sparfloxacin against streptococci, 1.27 ,ug/ml after a single dose of 400 mg and steady-state Sparfloxacin is a promising agent for a wide range of gram-positive and gram-negative infections; clinical trials will determine its ultimate role in the treatment of infectious diseases.
